ATB Capital Markets analyst David Kideckel says there are number of reasons why investors should be ... Read More
AltaCorp Capital analyst David M. Kideckel likes the disruptive potential of Willow Biosciences (Wil... Read More
With sales of cannabinoids expected in two years’ time, Willow Biosciences (Willow Biosciences Sto... Read More